与线粒体相关的编程细胞死亡模式用于预测非小细胞肺癌的预后
Xueyan Shi1, Sichong Han1, Guizhen Wang1
1State Key Laboratory of Molecular Oncology & Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Frontiers of medicine
|November 22, 2024
概括
这项研究开发了一种线粒体相关编程细胞死亡 (mtPCD) 的18基因风险评分模型,以预测非小细胞肺癌 (NSCLC) 的预后. 高风险得分表明存活率较低,但对免疫治疗的潜在敏感性较低.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 线粒体是编程细胞死亡 (PCD) 途径的核心.
- 线粒体相关的PCD (mtPCD) 有助于疾病的发病.
- 在非小细胞肺癌 (NSCLC) 中mtPCD的预后作用需要进一步研究.
研究的目的:
- 在NSCLC中分析mtPCD模式.
- 使用mtPCD相关基因开发NSCLC的预后预测模型.
- 调查 mtPCD 模型,临床特征和治疗反应之间的关联.
主要方法:
- 分析了4个数据集中的977名NSCLC患者的转录学,基因组学和临床数据.
- 开发一个18基因风险评分评估系统.
- 构建一个整合风险评分和临床因素的名录.
- 验证与受体相互作用的氨酸/氨酸蛋白激酶2 (RIPK2) 的表达和功能.
主要成果:
- 基于12个mtPCD模式的高风险评分与较差的NSCLC预后有关.
- 风险得分与临床病理特征,瘤突变负担和免疫治疗反应相关.
- 高风险的NSCLC患者显示Treg细胞透率增加,但瘤突变负担更高,表明潜在的免疫治疗敏感性.
- RIPK2被确定为一种致癌因子,与NSCLC总生存率相反相关.
结论:
- mtPCD基因模型和RIPK2是预测NSCLC预后的准确和实际工具.
- 这些发现突显了mtPCD在NSCLC病原和患者分层中的重要性.
- 针对mtPCD通路,包括RIPK2,可能为NSCLC提供新的治疗策略.
相关概念视频
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:30Overview of Cell Death
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...